Mori, Joakin O. http://orcid.org/0000-0002-9033-8536
Elhussin, Isra
Brennen, W. Nathaniel http://orcid.org/0000-0001-9807-7433
Graham, Mindy K. http://orcid.org/0000-0003-2521-0373
Lotan, Tamara L. http://orcid.org/0000-0002-0494-9067
Yates, Clayton C.
De Marzo, Angelo M. http://orcid.org/0000-0003-4847-5307
Denmeade, Samuel R.
Yegnasubramanian, Srinivasan http://orcid.org/0000-0003-0744-6606
Nelson, William G. http://orcid.org/0000-0002-4379-0730
Denis, Gerald V. http://orcid.org/0000-0001-9886-0401
Platz, Elizabeth A. http://orcid.org/0000-0003-3676-8954
Meeker, Alan K.
Heaphy, Christopher M. http://orcid.org/0000-0003-4264-1810
Article History
Accepted: 3 October 2023
First Online: 31 October 2023
Competing interests
: T.L.L. has received research support from Roche/Ventana, AIRA Matrix, DeepBio and Myriad Genetics for other studies. C.C.Y. received honorarium or consultant fees from PreludeDx, QED Therapeutics, Amgen, Regeneron and Riptide Bioscience. C.C.Y. is a shareholder in Riptide Bioscience. A.M.D.M. has served as a Consultant for Merck and Cepheid and has received research grant funding from Janssen R&D. S.R.D. has received research funding for his institution from Astellas and Bayer. S.Y. has received grant support to his institution from Janssen, Bristol Myers Squibb and Cepheid. He has also previously served as a consultant to Cepheid. W.G.N. is a member of the Scientific Advisory Board for Cepheid and has received funding support from Bristol Myers Squibb. G.V.D. is a member of the scientific advisory board of Vyne Therapeutics. The other authors declare no competing interests.